Tranexamic acid and trauma: Current status and knowledge gaps with recommended research priorities

Anthony E. Pusateri, Richard B. Weiskopf, Vikhyat Bebarta, Frank Butler, Ramon F. Cestero, Irshad H. Chaudry, Virgil Deal, Warren C. Dorlac, Robert T. Gerhardt, Michael B. Given, Dan R. Hansen, W. Keith Hoots, Harvey G. Klein, Victor W. MacDonald, Kenneth L. Mattox, Rodney A. Michael, Jon Mogford, Elizabeth A. Montcalm-Smith, Debra M. Niemeyer, W. Keith PrusaczykJoseph F. Rappold, Todd Rassmussen, Francisco Rentas, James Ross, Christopher Thompson, Leo D. Tucker

Research output: Contribution to journalReview articlepeer-review

88 Scopus citations


A recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies, there has been growing interest in the use of TXA for trauma. Potential adverse effects of TXA have also been reported. A US Department of Defense committee conducted a review and assessment of knowledge gaps and research requirements regarding the use of TXA for the treatment of casualties that have experienced traumatic hemorrhage. We present identified knowledge gaps and associated research priorities. We believe that important knowledge gaps exist and that a targeted, prioritized research effort will contribute to the refinement of practice guidelines over time.

Original languageEnglish (US)
Pages (from-to)121-126
Number of pages6
Issue number2
StatePublished - Feb 2013
Externally publishedYes


  • Tranexamic acid
  • efficacy
  • research requirements
  • safety
  • trauma

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine


Dive into the research topics of 'Tranexamic acid and trauma: Current status and knowledge gaps with recommended research priorities'. Together they form a unique fingerprint.

Cite this